MITOCAREX BIO LTD
MITOCAREX BIO LTD
Industry:
Biotechnology
Founded:
2022-02-01
Address:
Tel Aviv-jaffa, Tel Aviv, Israel
Country:
Israel
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
700 K USD
Investors List
SciSparc
SciSparc investment in Venture Round - MitoCareX Bio Ltd
More informations about "MitoCareX Bio Ltd"
Main - MitoCareX Bio
MitoCareX Bio was founded in 2022 with the goal to utilize its computational chemistry knowledge and know how in the field of Mitochondrial Carriers in order to develop new transformative medicines. Partner with us. MITOLINE. Our …See details»
MitoCareX Bio - Crunchbase Company Profile & Funding
Organization. MitoCareX Bio . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. About. MitoCareX Bio is a …See details»
MitoCareX Bio 2025 Company Profile: Valuation, Investors
MitoCareX Bio General Information Description. Developer of novel therapies intended for treating resistant cancers. The company platform utilizes an algorithm to model, predict, and discover small molecules that target mitochondrial carriers, enabling the oncology market to address …See details»
MitoCareX Bio Ltd - LinkedIn
MitoCareX Bio Ltd | 136 followers on LinkedIn. A drug discovery company developing novel treatments for hard-to-treat resistant lung cancer | MitoCareX Bio is a drug discovery company focusing on ...See details»
N2OFF to acquire biotech firm MitoCareX in strategic move
Feb 26, 2025 NEVE YARAK, Israel - N2OFF, Inc. (NASDAQ: NITO), a company specializing in clean technology and sustainable solutions, announced it has signed a definitive agreement to acquire MitoCareX Bio Ltd., a biotech company focused on developing cancer therapeutics. …See details»
MitoCareX Bio Ltd. (MitoCareX Bio Ltd.) - 药物管线_专利_临床试 …
The intended selling valuation represents an increase of 47% from the valuation at the time of SciSparc’s initial investment in MitoCareX Bio TEL AVIV, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty …See details»
N2OFF Announces Acquisition of MitoCareX Bio Ltd. - TipRanks
Feb 26, 2025 An announcement from N2OFF ( ) is now available. On February 26, 2025, N2OFF announced a definitive agreement to acquire MitoCareX Bio Ltd., a biotech company specializing in computational drug discovery targeting hard-to-treat cancers. The acquisition …See details»
MitoCareX Bio - Funding, Financials, Valuation & Investors
MitoCareX Bio is a biotechnology company that focuses on drug discovery for cancers & other life-threatening diseases. Search Crunchbase. Start Free Trial . ... How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of …See details»
MITOCAREX BIO LTD Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for MITOCAREX BIO LTD of TEL AVIV-JAFFA, Central District. Get the latest business insights from Dun & Bradstreet.See details»
MitoCareX Bio - VentureRadar
" Founded in 2022, MitoCareX Bio is a joint venture of SciSparc Ltd. The company will focus on investigating mitochondrial carriers, transport proteins crucial for cell viability. The company will focus on investigating mitochondrial carriers, transport proteins crucial for cell viability.See details»
MitoCareX Bio - Updates, News, Events, Signals & Triggers
Organization. MitoCareX Bio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Growth Insight Details. Powered by AI . Edit Growth Insight Details Section. MitoCareX Bio may be growing as it has been reported to have …See details»
SciSparc's JV MitoCareX Bio Launches its Advanced New …
Jul 7, 2022 The new facility will serve the JV’s development of potential cancer drugs TEL AVIV, Israel, July 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a ...See details»
SciSparc's Drug Discovery Joint Venture MitoCareX Bio
Feb 17, 2023 As a result of MitoCareX Bio meeting this milestone, SciSparc will invest an additional $400,000 in MitoCareX Bio and increase its share ownership in MitoCareX Bio from 31.48% to 41.92%.See details»
SciSparc Announces Positive Results for MitoCareX Bio with its …
Nov 27, 2023 MitoCareX Bio has met its second milestone as part of its joint venture agreement with the Company TEL AVIV, Israel, Nov. 27, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or ...See details»
MitoCareX Bio - VentureRadar
Founded in 2022, MitoCareX Bio is a joint venture of SciSparc Ltd. The company will focus on investigating mitochondrial carriers, transport proteins crucial for cell viability.See details»
MitoCareX Bio Company Profile: Overview and Full News Analysis
SciSparc signs non-binding letter of intent to sell its ownership interest in MitoCareX Bio Ltd. The intended selling valuation represents an increase of 47% from the valuation at the time of Scisparcs initial investment . The company is a specialty clinical-stage pharmaceutical …See details»
SciSparc Signs Definitive Agreement to Sell MitoCareX, …
TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced it has …See details»
Loan Agreement, dated March 12, 2025, among the Company, …
Mar 12, 2025 EX-10.1 2 ex10-1.htm . Exhibit 10.1 . LOAN AGREEMENT . This Agreement (the “Agreement”) is effective as of March 12, 2025 by and between MitoCareX Bio Ltd., a private company incorporated under the laws of the State of Israel, whose principal address is at 40 …See details»
SciSparc's Drug Discovery Joint Venture MitoCareX Bio …
TEL AVIV, Israel, May 08, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of ...See details»
Scisparc’s Mitocarex Bio JV develops algorithm to model human ...
May 9, 2023 Scisparc Ltd.’s drug discovery joint venture, Mitocarex Bio, has successfully developed its core algorithm for allowing the generation of reliable 3D comparative models of human SLC25A mitochondrial carrier proteins. 3D models of mitochondrial transporters are a …See details»